Department of Pathology, Immunology and Laboratory Medicine, College of Medicine, University of Florida, Gainesville, FL, USA.
Int J Surg Pathol. 2024 Feb;32(1):91-96. doi: 10.1177/10668969231166295. Epub 2023 Apr 12.
Hyalinizing trabecular tumor (HTT), a rare low-malignant-potential thyroid neoplasm, is usually treated with conservative surgery. However, cytomorphological diagnosis of HTT is challenging due to the significant overlap of nuclear features with more common malignancies such as papillary thyroid carcinoma (PTC), which usually requires more radical surgical intervention. To avoid unnecessary overtreatment, a precise diagnosis of HTT is therefore essential. Advances in molecular diagnostics provide the opportunity to overcome the limitations of cytological analysis. We present a case of HTT in a 71-year-old male who was initially suspected to be PTC based on cytopathology. However, further molecular analysis revealed gene fusion, classifying the lesion as HTT and preventing surgical overtreatment. We discuss the diagnostic pitfall of cytopathology in HTT and suggest using emerging molecular genetic tools to avoid it.
玻璃样小梁状肿瘤(HTT)是一种罕见的低恶性潜能甲状腺肿瘤,通常采用保守手术治疗。然而,由于 HTT 的核特征与更常见的恶性肿瘤(如甲状腺乳头状癌 [PTC])有很大的重叠,因此其细胞形态学诊断具有挑战性,而 PTC 通常需要更激进的手术干预。为了避免不必要的过度治疗,因此对 HTT 进行准确诊断至关重要。分子诊断学的进步为克服细胞学分析的局限性提供了机会。我们报告了一例 71 岁男性 HTT 病例,该患者最初基于细胞病理学被怀疑为 PTC。然而,进一步的分子分析显示出基因融合,将病变归类为 HTT,从而避免了过度手术治疗。我们讨论了 HTT 细胞病理学诊断中的陷阱,并建议使用新兴的分子遗传学工具来避免这种情况。